From the FDA Drug Label
The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.
There is no direct information in the provided drug label that supports an equivalent dose of Mounjaro for a patient currently taking Ozempic 2mg weekly. The FDA label for Mounjaro does not provide a direct comparison or conversion from Ozempic to Mounjaro dosing 1.
From the Research
When switching from Ozempic 2mg weekly to Mounjaro (tirzepatide), the equivalent starting dose would be Mounjaro 5mg weekly, as this dose has been shown to be effective in reducing HbA1c and body weight in patients with type 2 diabetes, as demonstrated in a study published in 2024 2. However, it's generally recommended to start at a lower dose of Mounjaro 2.5mg weekly for 4 weeks, then increase to 5mg for 4 weeks before considering further increases if needed, as this gradual titration helps minimize gastrointestinal side effects that commonly occur when starting GLP-1/GIP medications. Mounjaro works through dual GLP-1 and GIP receptor activation, while Ozempic only targets GLP-1 receptors, which explains why Mounjaro may have stronger effects at equivalent doses, as supported by a study published in 2021 3. Some key points to consider when making this switch include:
- The importance of gradual titration to minimize gastrointestinal side effects
- The potential for different side effect profiles between Ozempic and Mounjaro
- The need for monitoring during the transition period to ensure appropriate dosing and to address any adverse effects
- The consideration of individual patient factors, such as medical history, weight loss goals, and tolerance to these medications, as emphasized in a review published in 2025 4. You should not abruptly stop Ozempic and start Mounjaro at full dose, as this transition should be managed by your healthcare provider who can consider your specific medical history, weight loss goals, and tolerance to these medications, and adjust the dosing accordingly, as suggested by a study published in 2024 2. Always consult with your prescriber before making this switch to ensure appropriate dosing and monitoring, and to discuss the potential benefits and risks of Mounjaro, as well as any necessary adjustments to your treatment plan, as recommended in a study published in 2025 5.